WST
West Appoints Michel Lagarde to be President and Chief Executive Officer
Article Summary
BUY- West Pharmaceutical Services Inc. (NYSE: WST) announced that its Board of Directors has appointed Michel Lagarde to be President and Chief Executive Officer and a member of West Pharmaceutical Services,'s Board of Director starting August 31, 2026, succeeding Eric M.
- Green who will retire from his roles as President, CEO and Board Chair on that date.
- The global leader in innovative solutions for injectable drug administration also announced as part of the CEO transition that the Board has elected Lead Independent Director Robert F.
- Friel to become Board Chair effective August 31 of 2026.
- Lagarde brings extensive global experience helping pharmaceutical and biotech companies succeed by delivering critical products and services most recently as Executive Vice President of Thermo Fisher Scientific Inc., with responsibility for majority of company's businesses, joining Thermo in 2017 as Senior Vice President and President Pharma Services through acquisition of Patheon N.V., and previously served as President of JLL Partners from 2008 to 2016.
- Earlier in his career, Mr Lagarde spent 12 years at Philips in range of finance roles across several international markets.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 11.2% | 25% | 50.0 ptsMeets Minimum (11.2%) - Passes screener |
| EPS Growth Next 5Y ? | 13.8% | 25% | 35.0 ptsBelow Screener (13.8%) - Modest outlook |
| Target Price Upside ? | 12.4% | 20% | 50.0 ptsMeets Minimum (12.4%) - Target: $355.62 vs Current: $316.30 |
| Gross Margin % ? | 36.3% | 15% | 60.0 ptsSolid (36.3%) - Decent margins |
| Drawdown from 52-Wk High ? | -4.4% | 15% | 20.0 ptsBarely a Dip (-4.4%) - Near recent highs |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About WST
- West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
- It operates in two segments, Proprietary Products and Contract-Manufactured Products.
- The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products.
- This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support.
- This segment serves biologic, generic, and pharmaceutical drug companies.
- The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
- This segment primarily serves pharmaceutical, diagnostic, and medical device companies.
- It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors.
- West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.